Relmada Therapeutics, Inc. (RLMD) Financials

RLMD Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 235.4 million 16.6 million
Dec. 31, 2025 94.0 million 7.5 million
Sept. 30, 2025 14.9 million 5.4 million
June 30, 2025 21.1 million 5.2 million

RLMD Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.1 million 956186
Dec. 31, 2025 -14.6 million 3.2 million
Sept. 30, 2025 -6.7 million 3.6 million
June 30, 2025 -6.4 million 3.5 million

RLMD Net Income

No data available :(

RLMD Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 234.0 million - -
Dec. 31, 2025 93.0 million - -
Sept. 30, 2025 13.9 million - -
June 30, 2025 20.6 million - -

RLMD Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 86.6 million
Dec. 31, 2025 68.3 million
Sept. 30, 2025 33.2 million
June 30, 2025 33.2 million

RLMD Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 8.1 million 11.4 million -
Dec. 31, 2025 - 8.1 million 12.3 million -
Sept. 30, 2025 - 4.0 million 6.3 million -
June 30, 2025 4 2.8 million 7.4 million -

RLMD Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

RLMD

Price: $6.50

52 week price:
0.52
8.00

Earnings Per Share: -1.09 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 144200

Market Capitalization: 462.7 million

Links: